Response to the letter to the editor: Methodological considerations on “Comparison of dexmedetomidine and morphine versus plain ropivacaine 0.2% for myofascial infiltration in thoracolumbar spinal fusion: a double-blind randomized trial” Authors: Sandeep Dey, Stuti Bhamri, Ankita Jaiswal, Kanika Gupta, Mukesh Mohan Gupta, Ashutosh Kumar Published: 2026 We extend our gratitude to the authors for their appreciation of our study on multimodal analgesia for spine fusion surgeries [1]. We also wish to thank them for raising two very important queries. Regarding the first point, according to our study protocol, fentanyl infusion was administered exclusively when patients reported a Visual Analog Scale (VAS) score of ≥3 and was discontinued when the VAS score fell below 3. Consequently, fentanyl infusion was utilized solely for breakthrough pain that was inadequately managed with local anesthetic, with or without adjuvant, in conjunction with paracetamol (20 mg/kg) administered at skin closure and every 8 hours thereafter. Although for the purpose of the study, VAS scores were reported immediately after extubation and at 30 minutes, 1, 2, 3, 4, 8, 12, 16, 20, and 24 hours postoperatively, they were actually measured immediately after extubation, at 30 minutes, and then every hourly until 24 hours postoperatively. Hence, the fentanyl dose mentioned is the actual consumption over 24 hours, rather than a summation of the aforementioned 11 time points. The need for rescue analgesic (fentanyl) was triggered in all patients, except in two patients in the ropivacaine with morphine (RM) group. The total (mean±standard deviation) duration of fentanyl infusion was 124.8 (10.85±1.98) hours, 92.8 (8.06±1.28) hours, and 57.1 (4.96±1.36) hours in the groups ropivacaine (R), ropivacaine with dexmedetomidine (RD), and RM, respectively. Second, we acknowledge the observation regarding the statistical limitation of the VAS score across the 11 time points, as indicated in the study. The timeweighted average VAS scores in our investigation were 2.27±0.3, 1.87±0.32, and 1.21±0.4 for groups R, RD, and RM, respectively. A comparative analysis of these time-weighted average VAS scores demonstrated a statistically significant difference between groups R and RD (2.27±0.3 vs. 1.87±0.32, p<0.001), groups R and RM (2.27±0.3 vs. 1.21±0.4, p<0.001), and groups RD and RM (1.87±0.32 vs. 1.21±0.4, p<0.001). Subgroup analysis further revealed a consistent trend among patients undergoing single-level or two-to three-level spine fusion surgery.